Back to search

Article

Immunogenicity Against Wild-Type and Omicron SARS-CoV-2 After a Third Dose of Inactivated COVID-19 Vaccine in Healthy Adolescents

2022-05-20

Abstract excerpt

Background: Two doses of inactivated SARS-CoV-2 vaccine CoronaVac cannot elicit high efficacy against symptomatic COVID-19, especially against the Omicron variant, but that can be improved by a third dose in adults. The use of a third dose of CoronaVac in adolescents may be supported by immunobridging studies in the absence of efficacy data. <br><br>Methods: With an immunobridging design, our study (NCT04800133)...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
dc021787-1218-5fbe-9535-1c52cf368a8e
DOI
10.2139/ssrn.4115862
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immunogenicity Against Wild-Type and Omicron SARS-CoV-2 After a Third Dose of Inactivated COVID-19 Vaccine in Healthy AdolescentsDOI 10.2139/ssrn.4115862
Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical TrialSemantic proximity
Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after the third dose of BNT162b2 in healthy adolescentsSemantic proximity
Immunogenicity and reactogenicity of SARS-CoV-2 mRNA and inactivated vaccines in healthy adolescentsSemantic proximity
Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: a phase 3, randomized, placebo-controlled trial (PREVENT-19)Semantic proximity
Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow upSemantic proximity
Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVacSemantic proximity
Protection against symptomatic disease with the delta and omicron BA.1/BA.2 variants of SARS-CoV-2 after infection and vaccination in adolescents: national observational test-negative case control study, August 2021 to March 2022, EnglandSemantic proximity
The BTN162b2 Vaccine Induces Humoral and Cellular Immune Memory to Wuhan Strain SARS-CoV-2 and the Omicron Variant in Children 5 to 11 Years of AgeSemantic proximity
Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in AdolescentsSemantic proximity
Immunologic response, Efficacy, and Safety of Vaccines Against COVID-19 Infection in Children and Adolescents Aged 2 – 21 years old: A Systematic ReviewSemantic proximity
Clinical and Humoral Immune Response Characterization of SARS-CoV-2 Omicron BA.2.38 Infection in Pediatric PatientsSemantic proximity
Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses Against the SARS-CoV-2 Omicron Variant in Adolescents and AdultsSemantic proximity
Select a neighboring publication to make it the new centre.